uilt, led and advised life science companies. Previously, Mr. Mace was Vice Director and Senior Project Manager, Group Planning and Special Projects, with F. Hoffman-La Roche Ltd., where he provided financial analysis in support of long range business planning. Prior to that, Mr. Mace was Vice President, Finance and Global Operations at mtm laboratories AG, an in vitro diagnostics company, which developed and commercialized a portfolio of products using its patent protected biomarkers for early detection and diagnosis of cervical cancer. In this role, he was responsible for strategic and operational planning, budgeting, business development modeling, cash management and financial reporting. Mr. Mace also held positions of increasing responsibility with life science companies ViaCell, Inc., Cytyc Corporation and Boston Scientific Corpora

 uilt, led and advised life science companies. Previously, Mr. Mace was Vice Director and Senior Project Manager, Group Planning and Special Projects, with F. Hoffman-La Roche Ltd., where he provided financial analysis in support of long range business planning. Prior to that, Mr. Mace was Vice President, Finance and Global Operations at mtm laboratories AG, an in vitro diagnostics company, which developed and commercialized a portfolio of products using its patent protected biomarkers for early detection and diagnosis of cervical cancer. In this role, he was responsible for strategic and operational planning, budgeting, business development modeling, cash management and financial reporting. Mr. Mace also held positions of increasing responsibility with life science companies ViaCell, Inc., Cytyc Corporation and Boston Scientific Corpora